Illumina

“The culture of giving back is strongly embedded at Illumina,” says Vanessa Light, Senior Manager of Corporate Social Responsibility. “It is inspiring to see how engaged and excited our employees are to share their expertise and skills in support of our communities.” During #GlobalVolunteerMonth, we’re celebrating employees who are stepping up in big ways: leading hands-on STEM experiments, cleaning up communities, and inspiring the next generation of scientists. See how employees are getting involved: https://bit.ly/42kibpq #IlluminaProud

Unlock deeper biological insights 🔓🧬 We are excited to announce that Illumina Connected Multiomics is now available for early access, Illumina's first fully integrated multiomic analysis software enabling any lab to seamlessly move from sample to insights for Bulk-RNA, Single Cell, proteomics or Spatial assays. With pre-configured and fully customizable workflows that enable powerful statistical analysis with a easy to use interactive interface, and the ability to export publication-ready visualizations, and no-touch integration with Illumina software, instruments, and assays, Connected Multiomics is the platform for multiomic insight and analysis. Learn more about this new multiomic analysis software here: https://lnkd.in/gjwgNACh If you are at # #BioITWorldExpo, drop by the Illumina booth #704 to learn more. #sequencing #spatial #singleCell #proteomics #bioinformatics

Can genomic testing improve cardiovascular care? Henry Ford Health and Illumina are exploring that question in the CardioSeq study, which is assessing whether whole-genome sequencing (WGS) can provide meaningful insights for patients with heart conditions. Of the first 1,000 patients enrolled, genomic findings were discovered in 22%, including 100 individuals identified at increased risk for cardiovascular disease. As the study continues, researchers will evaluate how genomic information influences treatment decisions and long-term health outcomes. GenomeWeb has more on the initial findings, which were highlighted at the American College of Cardiology annual scientific meeting: https://bit.ly/41VsvVY #ACC25 #IlluminaProud

Meagan McLeod, Illumina staff global market entry manager, specializes in making sure new products are set for success in every market. For the MiSeq i100 Series, she worked to enable sales in 150+ countries, overcoming complex regulations and ensuring product guides in 40+ languages. Expanding access to genomics takes strategy, persistence, and teamwork. Read how Meagan and the team made it happen: https://bit.ly/3FOHPuR

Every day, babies are born with undetected genetic conditions—with diagnosis taking nearly five years on average from onset of symptoms. Whole genome sequencing (WGS) is helping change this through groundbreaking studies like Generation (UK) and GUARDIAN (US), in which early data demonstrates WGS identified serious health conditions in 120 newborns, and only 10 of these newborns’ conditions were detected by traditional screening. "We expect WGS to become standard, especially in nationalised healthcare settings." - Swaroop Aradhya, Global Head of Medical and Clinical Affairs at Illumina From life-saving bone marrow transplants to simple vitamin supplements, early detection enables timely intervention. Read Medical Device Network's article about how genomic sequencing is transforming newborn screening: https://bit.ly/4iLGALl

Fresh off his #ABRF25 talk, “The MiSeq i100 in the core facility: Where have you been all my life?” Alvaro G. Hernandez, Ph.D., lab director and MiSeq i100 Plus beta tester, is letting us peek at his work in DNA Services at the University of Illinois at Urbana-Champaign. https://bit.ly/423PIny

Ali Crawford, Ph.D., Sr. Director of Scientific Research, has dedicated her career to tackling one of healthcare's most vexing challenges: rare disease. Her passion drives a relentless pursuit to unlock the genome's hidden secrets. At #ACMGMtg25, she presented updates on our constellation technology—pushing the boundaries of what's possible with short read genomes. Constellation represents a fundamental shift in how we interrogate the genome. This innovation brings library prep directly onto the flow cell and illuminates previously inaccessible genomic regions. For individuals searching for genetic answers, this means potentially life-changing insights. When constellation launches in 1H 2026, it promises to transform translational applications with unprecedented workflow simplicity and comprehensive genomic visibility. Learn more: https://bit.ly/3D7d2IM. #IlluminaProud #RareDisease #PrecisionMedicine

Thank you to everyone who joined us at the Illumina Innovation Showcase last night at the Assn of Biomolecular Resource Facilities (ABRF) annual meeting. It’s always great to spend time with Core Directors to hear about the challenges they are facing and get feedback on our products and offerings. I was joined by Dr. Alvaro G. Hernandez, Ph.D., Director of DNA services Uni. of Illinois Urbana- Champaign, who gave a wonderful and insightful overview of his experience with the MiSeq i100 and the power and flexibility it brought to his lab, and Dr. Emily Parker of Illumina, who summarized the latest advances in our multiomic early access offerings ranging from Illumina Protein Prep, 5-base genome, single-cell, and our newest spatial platform. Illumina technology is designed to unlock deeper insights, power your multiomic discovery, and transform what’s possible in genomics and multiomics. Watch this space for more details from our innovation roadmap: https://lnkd.in/ghDy-J46  

At #ACMGMtg25 last week, we presented three posters that demonstrated the value of whole-genome sequencing (WGS) in interrogating challenging regions of the genome and providing rare genetic disease diagnoses. We sat down with Denise Perry, Sr. Director of Medical Genomics Laboratory Services, to talk about these posters, their findings, and the future of WGS: https://bit.ly/4iWKMYz

Chief Technology Officer, Steven Barnard, PhD compares multiomics to pointillist paintings, in which thousands of dots (or omics data points) come together to reveal a clearer image. Steve says, "unleashing the full potential of multiomics will transform everything, from the pace of scientific discovery and how quickly new drugs come to market to how we diagnose, detect, and treat life-threatening disease." Read Steve's perspective on how Illumina is uniquely positioned to bring multiomics to scale: https://bit.ly/41Y02xs